SCHEMBL28773753

SCHEMBL28773753

NS(=O)(=O)CCC1COc2ccccc2O1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 6/20 0.68
HTT P42858 1/20 0.57
MEN1 O00255 1/20 0.53
TSHR P16473 1/20 0.53
KMT2A Q03164 1/20 0.53
ALOX5 P09917 1/20 0.50
HTR1A P08908 1/20 0.50
ADRA2A P08913 1/20 0.50
DRD1 P21728 1/20 0.50
TBXA2R P21731 1/20 0.50
SLC6A2 P23975 1/20 0.50
ADRA1A P35348 1/20 0.50
DRD3 P35462 1/20 0.50
CA1 P00915 1/20 0.49
CA4 P22748 1/20 0.49
CA5A P35218 1/20 0.49
CA9 Q16790 1/20 0.49
CA5B Q9Y2D0 1/20 0.49
MAPT P10636 1/20 0.48
PKM P14618 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL438555 0.81 CA2 (1.00) CA2HTTMEN1TSHRKMT2A
SCHEMBL1568393 0.78 HTT (0.66) CA2HTTALOX5HTR1AADRA2A
SCHEMBL406531 0.78 HTT (0.61) CA2HTTALOX5HTR1AADRA2A
SCHEMBL9451259 0.77 CA2 (0.64) CA2HTTALOX5HTR1AADRA2A
SCHEMBL437933 0.77 CA2 (1.00) CA2CA1LMNAALDH1A1SMN1; SMN2
SCHEMBL441036 0.77 CA2 (1.00) CA2CA1LMNAALDH1A1SMN1; SMN2
Hydrochloric Acid SCHEMBL8179101 0.77 HTT (0.59) CA2HTTALOX5HTR1AADRA2A
SCHEMBL12309752 0.75 POLB (0.62) CA2HTTTSHRHTR1AADRA2A
SCHEMBL8788249 0.75 HTT (0.61) CA2HTTHTR1AADRA2ADRD1
SCHEMBL5871673 0.75 HTT (0.61) CA2HTTALOX5HTR1AADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101378746-B Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain JANSSEN PHARMACEUTICA NV 2013-07-17 CN disclosed
CN-101336106-B Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression JANSSEN PHARMACEUTICA NV 2012-09-05 CN disclosed
CN-101374512-B Use of benzo-fused heterocycle sulfamide for preparing neuroprotective agent JANSSEN PHARMACEUTICA NV 2012-07-04 CN disclosed
CN-101365442-B Use of benzo-fused heterocycle sulfamide derivatives for preparing medicine for the treatment of obesity JANSSEN PHARMACEUTICA NV 2011-11-16 CN disclosed
CN-101365441-B Use of benzo-fused heterocycle sulfamide derivatives for the preparation of a medicament for lowering lipid levels and lowering blood glucose levels JANSSEN PHARMACEUTICA NV 2011-11-16 CN disclosed
CN-101370495-B Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder JANSSEN PHARMACEUTICA NV 2011-10-19 CN disclosed
CN-101378746-A Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain JANSSEN PHARMACEUTICA NV (BE) 2009-03-04 CN disclosed
CN-101374512-A Use of benzo-fused heterocycle sulfonamides as neuroprotective agents JANSSEN PHARMACEUTICA NV (BE) 2009-02-25 CN disclosed
CN-101374513-A Use of benzo-fused heterocycle sulfamide derivatives for disease remission/epileptogenesis JANSSEN PHARMACEUTICA NV (BE) 2009-02-25 CN disclosed
CN-101370495-A Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder JANSSEN PHARMACEUTICA NV (BE) 2009-02-18 CN disclosed
CN-101370494-A Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction JANSSEN PHARMACEUTICA NV (BE) 2009-02-18 CN disclosed
CN-101365442-A Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity JANSSEN PHARMACEUTICA NV (BE) 2009-02-11 CN disclosed
CN-101365441-A Use of benzo-fused heterocycle sulfamide derivatives for lowering lipid levels and lowering blood glucose levels JANSSEN PHARMACEUTICA NV (BE) 2009-02-11 CN disclosed
CN-101336106-A Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression JANSSEN PHARMACEUTICA NV (BE) 2008-12-31 CN disclosed